This journal covers clinical practice and translational research and clinical applications of approved and experimental radiopharmaceuticals for diagnostic and therapeutic purposes, benefiting a wide readership of nuclear medicine and allied professionals.

The journal complies with ethical guidelines, authors have to declare any Conflict of Interest in detail. Authors must also state that they conformed with the Helsinki Declaration of 1975 concerning Human and Animal Rights, and that they followed out policy concerning Informed Consent. Further details about the ethical policies are available under "Ethics & Disclosure".

This is the journal of the Italian Association of Nuclear Medicine (AIMN). AIMN members have free access to the journal.

  • The journal’s field is molecular imaging using technologies ranging from morphological to functional and in vivo biochemical imaging.
  • It offers a comprehensive overview of validated applications and optimisation of use of imaging procedures.
  • It may also deal with radiation physics and biology and pharmacokinetics applied to translational and clinical imaging.
  • The journal targets clinical practitioners and professionals involved in preclinical development of molecular imaging for application in human subjects.

Journal information

Editor-in-Chief
  • Laura Evangelista
Publishing model
Hybrid. Open Access options available

Journal metrics

2.506 (2019)
Impact factor
20 days
Submission to first decision
38 days
Submission to acceptance
88,332 (2019)
Downloads

Latest articles

This journal has 51 open access articles

Journal updates

  • CATI received its first impact factor

    With great pleasure we announce the first impact factor of CATI.

    The impact factor 2019 is 2,506, found on rank 58 out of 133 in the category "Radiology, Nuclear Medicine & Medical Imaging".

    Thank you everybody for your support to achieve this milestone.

  • New Editor-in-Chief

    This is to announce that 

    Laura EVANGELISTA, MD PhD
    Nuclear Medicine Unit - Department of Medicine DIMED, University of Padua, Padua, Italy

    will be the Editor-in-Chief of Clinical and Translational Imaging

  • COVID-19 and impact on peer review

    As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times.  Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.

View all updates

Subscribe

eJournal
$99.00
Note this is only the net price. Taxes will be calculated during checkout.
  • Immediate online access with complete access to all articles
  • Downloadable in PDF format
  • Subscription expires 12/31/2020

About this journal

Electronic ISSN
2281-7565
Print ISSN
2281-5872
Abstracted and indexed in
  1. CNKI
  2. Dimensions
  3. EBSCO Discovery Service
  4. EMBASE
  5. Emerging Sources Citation Index
  6. Google Scholar
  7. INIS Atomindex
  8. Institute of Scientific and Technical Information of China
  9. Japanese Science and Technology Agency (JST)
  10. Naver
  11. OCLC WorldCat Discovery Service
  12. ProQuest Advanced Technologies & Aerospace Database
  13. ProQuest Central
  14. ProQuest SciTech Premium Collection
  15. ProQuest Technology Collection
  16. ProQuest-ExLibris Primo
  17. ProQuest-ExLibris Summon
  18. Reaxys
  19. SCImago
  20. SCOPUS
  21. Science Citation Index Expanded (SciSearch)
  22. Semantic Scholar
  23. UGC-CARE List (India)
Copyright information

Rights and permissions

Springer policies

© Italian Association of Nuclear Medicine and Molecular Imaging